Australia-based medical cannabis company Zelira Therapeutics Ltd. said Tuesday that clinical trials showed the company's medical marijuana drug candidate successfully treated chronic insomnia.
According to Zelira Therapeutics, the world-first clinical validation demonstrated that its ZTL-101 medical cannabis treatment is safe and effective for chronic insomnia. The results of the trial open prospects to launch and distribute this product in global markets including the U.S. in the second half of 2020, the company noted.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.